Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-8.67 Insider Own0.10% Shs Outstand394.12M Perf Week2.44%
Market Cap110.54B Forward P/E17.29 EPS next Y16.22 Insider Trans- Shs Float393.20M Perf Month-2.38%
Income-2997.10M PEG- EPS next Q3.36 Inst Own94.50% Short Float1.23% Perf Quarter-9.45%
Sales14.93B P/S7.40 EPS this Y-40.80% Inst Trans4.01% Short Ratio1.38 Perf Half Y-11.14%
Book/sh184.31 P/B1.52 EPS next Y5.15% ROA2.60% Target Price367.40 Perf Year-0.42%
Cash/sh5.25 P/C53.38 EPS next 5Y8.56% ROE5.30% 52W Range237.50 - 340.34 Perf YTD-10.25%
Dividend0.20 P/FCF35.60 EPS past 5Y-42.20% ROI-2.70% 52W High-17.59% Beta0.78
Dividend %0.07% Quick Ratio1.90 Sales past 5Y36.10% Gross Margin63.00% 52W Low18.10% ATR9.21
Employees21600 Current Ratio2.00 Sales Q/Q90.10% Oper. Margin-22.90% RSI (14)45.39 Volatility3.42% 3.23%
OptionableYes Debt/Eq0.59 EPS Q/Q46.60% Profit Margin20.90% Rel Volume0.77 Prev Close274.55
ShortableYes LT Debt/Eq0.56 EarningsFeb 22 BMO Payout0.00% Avg Volume3.52M Price280.48
Recom1.70 SMA20-1.58% SMA50-6.14% SMA200-6.51% Volume2,726,558 Change2.16%
Nov-24-15Reiterated Mizuho Buy $340 → $354
Nov-13-15Reiterated Mizuho Buy $337 → $340
Oct-28-15Reiterated Leerink Partners Outperform $311 → $342
Oct-09-15Initiated Mizuho Buy
Sep-29-15Initiated Nomura Buy
Aug-07-15Reiterated RBC Capital Mkts Outperform $361 → $375
Aug-07-15Reiterated Deutsche Bank Buy $346 → $350
Aug-03-15Resumed JP Morgan Overweight $375 → $400
Jul-28-15Reiterated Leerink Partners Outperform $354 → $388
Jul-28-15Reiterated Canaccord Genuity Buy $352 → $396
Jul-17-15Downgrade RBC Capital Mkts Top Pick → Outperform $361
Feb-13-16 09:20AM  3 Value Stocks Senior Citizens Could Buy Right Now at Motley Fool
Feb-12-16 06:27PM  Loeb's Allergan Stake Grows by 50% at The Wall Street Journal
06:00PM  Regeneron Pharmaceuticals Major Revenue Sources in 4Q15
05:16PM  ALLERGAN PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:26PM  Dan Loeb's Q4 trades
12:56PM  Five Foreign Stocks Hedge Funds Love at Insider Monkey
11:11AM  Inside the M&A Deals in the Health-Care Sector
08:09AM  Eli Lilly loses latest round in UK drug patent battle Reuters
Feb-11-16 03:01PM  Napier Park is Betting Big on Media General (MEG) and Allergan (AGN) for 2016; Plus 3 Other Major Moves at Insider Monkey
07:32AM  Teva Pharm Q4 profit, revenue fall as Copaxone sales drop
Feb-10-16 05:09PM  [$$] Mylan agrees to buy Sweden's Meda for $9.9bn including debt at Financial Times
12:00PM  3 Value Stocks Ready to Outperform at TheStreet
08:00AM  Allergan to Present at the RBC Capital Markets Healthcare Conference PR Newswire
Feb-09-16 04:21PM  Pfizer Gets Back to Growth at Motley Fool
11:35AM  Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan) at 24/7 Wall St.
10:58AM  Pfizers Loss of Product Exclusivity Affected Its 4Q15 Revenues
08:33AM  [$$] Pfizer seeks to soothe fears over R&D at Financial Times
Feb-08-16 01:42PM  Pfizer To Reorganize After Allergan Buyout, With Saunders President
10:26AM  Pfizer unveils management line up for combined company
10:22AM  [$$] Pfizer Outlines Post-Merger Management Slate at The Wall Street Journal
10:03AM  Pfizer Names New Executives to Run Units After Allergan Deal at Bloomberg
09:56AM  Pfizer to create operating unit after Allergan deal closes
09:30AM  Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction Business Wire
Feb-05-16 04:15PM  Shire's NDA Resubmission for Lifitegrast Accepted by FDA
07:00AM  Pfizer's Pipeline Productivity Is Improving at Morningstar
Feb-04-16 10:07AM  Expectations for Valeant Pharmaceuticals in 2016
08:05AM  Momentum, Strategy within Today's Market - Analyst Notes on Gilead Sciences, Schlumberger, Royal Caribbean Cruises and Allergan Accesswire
Feb-03-16 02:49PM  5 Stunning Numbers From Pfizer's Q4 Report That You May Have Missed at Motley Fool
08:10AM  Insight into the Performance of Interferon and Other Products
Feb-02-16 02:55PM  [$$] Pfizer Beats Expectations but Guidance Disappoints at The Wall Street Journal
02:41PM  Pfizer Looks Undervalued at Morningstar
02:26PM  [$$] Pfizer says US politicians will not scupper Allergan deal at Financial Times
01:48PM  Pfizer 2016 forecast disappoints
01:44PM  Pfizer earnings fall but tops Street 4Q forecasts
10:00AM  Pfizer Beats on Q4 Earnings, Revenues, Outlook Disappoints
Feb-01-16 01:07PM  Jim Cramer: Stop Thinking So Short Term About Biotech Stocks at TheStreet
01:04PM  Jim Cramer on Pfizer (PFE): 'One of the Most Consistent Companies' at TheStreet
Jan-29-16 03:02PM  3 Numbers That Will Matter When Pfizer Reports Its Fourth-Quarter Results at Motley Fool
11:53AM  Independent Baylor University Study Showcases Economic Impact of Allergan on Waco and Central Texas Economies at noodls
11:00AM  Independent Baylor University Study Showcases Economic Impact of Allergan on Waco and Central Texas Economies PR Newswire
08:21AM  Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD) at noodls
08:07AM  Johnson ControlsTyco Merger: The Pfizer-Allergan of 2016?
07:49AM  Allergan Announces Collaboration with AstraZeneca to Develop and Commercialize ATM-AVI (aztreonam and avibactam) for Antibiotic-Resistant Gram-Negative Infections at noodls
07:35AM  Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD) PR Newswire
07:05AM  Allergan Announces Collaboration with AstraZeneca to Develop and Commercialize ATM-AVI (aztreonam and avibactam) for Antibiotic-Resistant Gram-Negative Infections PR Newswire
Jan-28-16 09:00PM  Biotech Stocks Crashed and Nobody Knows Why at Fortune
08:36AM  Allergan: An Activist Investment Analysis (AGN,VRX) at Investopedia
Jan-27-16 01:21PM  As Ackman Goes On and off Best Hedge Fund List, Is He Shifting Styles?
07:24AM  Asanko Gold Mine Announces First Gold Production at noodls
Jan-26-16 04:30PM  Allergan's Botox Gains FDA Nod for Lower Limb Spasticity
09:35AM  Were Hedge Funds Right Betting On These Stocks in Q4? at Insider Monkey
Jan-25-16 06:31PM  After-hours buzz: LULU, AGN, SWFT & more at CNBC
04:10PM  Inversions like Johnson Controls-Tyco to hit corporate tax collection, CBO says at MarketWatch
Jan-24-16 10:44PM  [$$] Johnson Controls closes in on $20bn Tyco acquisition at Financial Times
Jan-22-16 04:58PM  The Best Billionaire Investor You've Never Heard Of & The Stock He's Doubling Down On at Forbes
04:25PM  More than just a pretty face: Inside Revance's efforts to create a Botox alternative for cosmetic, therapeutic uses (Photos) at
08:07AM  Revlimid Continues to Drive Celgenes Revenue
08:05AM  U.S. FDA Approves BOTOX® (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults PR Newswire
Jan-21-16 02:44PM  Follow Paul Ryan's lead on tax reform at CNBC
11:19AM  [$$] Five Pharma Picks for Another Volatile Year at
07:35AM  Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE® (dalbavancin) PR Newswire
07:05AM  VIBERZI (eluxadoline) Phase III Trial Results Published in The New England Journal of Medicine PR Newswire
Jan-20-16 11:40AM  Valeant Freefall Calls Equity Deals Into Question at The Wall Street Journal
10:27AM  Sanofi Rose 3.5%, Disclosed a Deal Worth up to 1.2 Billion Euros
08:00AM  Allergan to Report Fourth Quarter and Full-Year 2015 Earnings and Host Conference Call and Webcast PR Newswire
Jan-19-16 08:05AM  Rapastinel (GLYX-13) Shown to Improve Ketamine or PCP-Induced Cognitive Impairment in Mice PR Newswire
07:42AM  Where Could Pfizer Be in 10 Years? at Motley Fool
Jan-16-16 04:09PM  Heres How Andreas Halvorsens Viking Global Managed A Terrific Q4 at Insider Monkey
12:00PM  5 Stocks With Bigger Dividends Than General Electric at Motley Fool
Jan-14-16 12:00PM  More High-Quality Stocks Now in Buying Range at Morningstar
10:57AM  4 Can't-Miss Quotes From Pfizer's Top Executives Regarding Its Future at Motley Fool
09:20AM  How the New Allergan Plc Will Make Money at Investopedia
Jan-13-16 04:25PM  Arena, Boehringer Ingelheim Ink Deal, Schizophrenia in Focus
Jan-12-16 06:56PM  Pfizer, Allergan say combined drug pipeline 'underappreciated'
06:45PM  Drug Stocks Mixed On Guidance Updates at Investor's Business Daily
04:27PM  Pfizer, Allergan CEOs: Tie-up aims for growth, not cost cuts
04:25PM  Ironwood Highlights Strategic Objectives, Provides Outlook
04:14PM  Pfizer, Schwab, Chevron, Verizon All Belong in Your Portfolio, Says Swan Capital's President at TheStreet
01:30PM  Here's What To Buy In A Down Market
08:36AM  Mylan CEO: Dont think the answer is price controls on drugs
Jan-11-16 05:16PM  Irish drugmaker Shire in $32B deal for US-based Baxalta
12:40PM  Shire's Buy of Baxalta Is Pricey at The Wall Street Journal
12:11PM  Pfizer CEO: Drug pricing a political issue
12:07PM  Pfizer CEO: Majority of drugs developed by pharma industr...
07:19AM  How To Evaluate Healthcare Merger & Acquisition Deals at Motley Fool
Jan-10-16 08:03PM  Drugmakers Raise Prices Despite Criticisms
07:37AM  Pfizer Sets its Sights on Ireland at Motley Fool
Jan-09-16 12:01AM  [$$] 4 Who Beat the Market at
Jan-08-16 05:00PM  Pfizer hikes U.S. prices for over 100 drugs on January 1
04:23PM  Healthcare investors brace for busy week as U.S. conference kicks off Reuters
03:20PM  Allergan Acquires Anterios, Boosts Neurotoxin Pipeline
12:30PM  All Hope Is Not Lost in 2016
Jan-07-16 07:49PM  Jim Cramer's 'Mad Money' Recap: New Rules for a Tanking Market at TheStreet
10:06AM  The PfizerAllergan Deal: 4Q15 Brings the Biggest Pharma Merger
08:40AM  [$$] Allergan Inks $90 Million Deal for Anterios at The Wall Street Journal
08:18AM  Can 2016 Be a New Beginning for Pfizer Inc.? at Motley Fool
08:00AM  Allergan Acquires Medical Dermatology and Aesthetic Medicine Company Anterios to Expand Neurotoxin Pipeline PR Newswire
07:19AM  3 Attractive Income Stocks Whose Dividends Could Double at Motley Fool
Jan-06-16 05:06PM  S&P 500 Stocks With Highest Percentage Of Buy Ratings at Investor's Business Daily
04:49PM  Correction: Financial Markets-The Year in Deals story
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, generic, branded generic, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular, and anti-infective therapeutic categories, as well as dermatology and plastic surgery. It also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians' offices. In addition, Allergan plc is developing ocular implants that reduce intraocular pressure associated with glaucoma; and an intranasal neurostimulation device, as well as other dry eye products. Allergan plc has a global development and commercialization agreement with AstraZeneca Plc regarding investigational antibiotic combination ATM-AVI. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PYOTT DAVID E IChairman of the Board and CEOFeb 20Option Exercise0.001,3790166,379Feb 24 09:52 PM
Gangolli Julian SCVP & Pres, North AmericaFeb 20Option Exercise0.0051402,418Feb 24 09:44 PM